

Efficacy of a Tetravalent Dengue Vaccine in Healthy Children

New England Journal of Medicine

381, 2009-2019

DOI: [10.1056/nejmoa1903869](https://doi.org/10.1056/nejmoa1903869)

Citation Report

#	ARTICLE	IF	CITATIONS
1	A cohort study to assess the incidence of dengue, Brazil, 2014–2018. <i>Acta Tropica</i> , 2020, 204, 105313.	2.0	15
2	Safety and immunogenicity of a single dose of a tetravalent dengue vaccine with two different serotype-2 potencies in adults in Singapore: A phase 2, double-blind, randomised, controlled trial. <i>Vaccine</i> , 2020, 38, 1513-1519.	3.8	32
3	Antigenic Variation of the Dengue Virus 2 Genotypes Impacts the Neutralization Activity of Human Antibodies in Vaccinees. <i>Cell Reports</i> , 2020, 33, 108226.	6.4	43
4	Structure-guided paradigm shifts in flavivirus assembly and maturation mechanisms. <i>Advances in Virus Research</i> , 2020, 108, 33-83.	2.1	20
5	Dengue vaccine development by the year 2020: challenges and prospects. <i>Current Opinion in Virology</i> , 2020, 43, 71-78.	5.4	48
6	Rolling circle amplification: A high fidelity and efficient alternative to plasmid preparation for the rescue of infectious clones. <i>Virology</i> , 2020, 551, 58-63.	2.4	9
7	Time varying methods to infer extremes in dengue transmission dynamics. <i>PLoS Computational Biology</i> , 2020, 16, e1008279.	3.2	7
8	Live vaccine infection burden elicits adaptive humoral and cellular immunity required to prevent Zika virus infection. <i>EBioMedicine</i> , 2020, 61, 103028.	6.1	10
9	Protective and enhancing interactions among dengue viruses 1-4 and Zika virus. <i>Current Opinion in Virology</i> , 2020, 43, 59-70.	5.4	41
10	Cost-efficiency analysis of voluntary vaccination against n-serovar diseases using antibody-dependent enhancement: A game approach. <i>Journal of Theoretical Biology</i> , 2020, 503, 110379.	1.7	18
11	Conserved epitopes with high HLA-I population coverage are targets of CD8+ T cells associated with high IFN- γ responses against all dengue virus serotypes. <i>Scientific Reports</i> , 2020, 10, 20497.	3.3	5
12	The Impact of Serotype Cross-Protection on Vaccine Trials: DENVax as a Case Study. <i>Vaccines</i> , 2020, 8, 674.	4.4	18
13	Dengue: A Minireview. <i>Viruses</i> , 2020, 12, 829.	3.3	149
14	Modified mRNA-LNP Vaccines Confer Protection against Experimental DENV-2 Infection in Mice. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 18, 702-712.	4.1	38
15	Long-term Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Children and Adults: A Randomized, Placebo-Controlled, Phase 2 Study. <i>Journal of Infectious Diseases</i> , 2022, 225, 1513-1520.	4.0	5
16	Major Histocompatibility Complex Class I Chain-Related A and B (MICA and MICB) Gene, Allele, and Haplotype Associations With Dengue Infections in Ethnic Thais. <i>Journal of Infectious Diseases</i> , 2020, 222, 840-846.	4.0	5
17	Enhancement of Tetravalent Immune Responses to Highly Conserved Epitopes of a Dengue Peptide Vaccine Conjugated to Polystyrene Nanoparticles. <i>Vaccines</i> , 2020, 8, 417.	4.4	12
18	Sequential immunization induces strong and broad immunity against all four dengue virus serotypes. <i>Npj Vaccines</i> , 2020, 5, 68.	6.0	13

#	ARTICLE	IF	CITATIONS
19	Well-balanced immune response and protective efficacy induced by a single dose of live attenuated tetravalent dengue vaccine (KD-382) in monkeys. <i>Heliyon</i> , 2020, 6, e04506.	3.2	2
20	Dengue: current state one year before WHO 2010–2020 goals. <i>Acta Clinica Belgica</i> , 2022, 77, 436-444.	1.2	23
21	Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models. <i>EBioMedicine</i> , 2020, 60, 102991.	6.1	21
23	Mobilization and Activation of the Innate Immune Response to Dengue Virus. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 574417.	3.9	25
24	The continued threat of emerging flaviviruses. <i>Nature Microbiology</i> , 2020, 5, 796-812.	13.3	520
25	The Imperative of Dengue Vaccination for Children with Sickle Cell Disease. <i>Journal of Tropical Pediatrics</i> , 2020, 66, 245-247.	1.5	2
26	Dengue vaccines: the road to failure or to success?. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2677-2679.	3.3	1
27	Vaccines Against Dengue and West Nile Viruses in India: The Need of the Hour. <i>Viral Immunology</i> , 2020, 33, 423-433.	1.3	0
28	The Effects of Pre-Existing Antibodies on Live-Attenuated Viral Vaccines. <i>Viruses</i> , 2020, 12, 520.	3.3	47
29	A Non-structural 1 Protein G53D Substitution Attenuates a Clinically Tested Live Dengue Vaccine. <i>Cell Reports</i> , 2020, 31, 107617.	6.4	14
30	Identification of Dengue Virus Serotype 3 Specific Antigenic Sites Targeted by Neutralizing Human Antibodies. <i>Cell Host and Microbe</i> , 2020, 27, 710-724.e7.	11.0	25
31	Dengue vaccine: a key for prevention. <i>Expert Review of Vaccines</i> , 2020, 19, 499-506.	4.4	1
32	Adaptive Immunity to Dengue Virus: Slippery Slope or Solid Ground for Rational Vaccine Design?. <i>Pathogens</i> , 2020, 9, 470.	2.8	10
33	Cross-Reactive Immunity Among Flaviviruses. <i>Frontiers in Immunology</i> , 2020, 11, 334.	4.8	110
34	Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2–17 years: a randomised, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2020, 395, 1434-1443.	13.7	57
35	Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2020, 395, 1423-1433.	13.7	136
36	Cross-reactivity reduced dengue virus 2 vaccine has no cross-protection against heterotypic dengue viruses. <i>Future Virology</i> , 2020, 15, 79-90.	1.8	0
37	Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2456-2464.	3.3	19

#	ARTICLE	IF	CITATIONS
38	Anti-dengue Vaccines: From Development to Clinical Trials. <i>Frontiers in Immunology</i> , 2020, 11, 1252.	4.8	31
39	Human Vaccines & Immunotherapeutics: news. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2-3.	3.3	0
40	Habitat characteristics and insecticide susceptibility of <i>Aedes aegypti</i> in the Ifakara area, south-eastern Tanzania. <i>Parasites and Vectors</i> , 2020, 13, 53.	2.5	9
41	Dengue: Status of current and under development vaccines. <i>Reviews in Medical Virology</i> , 2020, 30, e2101.	8.3	49
42	What translatable knowledge from dengue vaccine design can we pass onto future anti-parasitic vaccine development?. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 391-395.	5.0	2
43	Dengue virus and the complement alternative pathway. <i>FEBS Letters</i> , 2020, 594, 2543-2555.	2.8	20
44	Tetavalent Dengue Vaccine in Healthy Children. <i>New England Journal of Medicine</i> , 2020, 382, 1769-1771.	27.0	0
45	Defeat Dengue and Zika Viruses With a One-Two Punch of Vaccine and Vector Blockade. <i>Frontiers in Microbiology</i> , 2020, 11, 362.	3.5	9
46	Arboviruses: A global public health threat. <i>Vaccine</i> , 2020, 38, 3989-3994.	3.8	105
47	Role of RNA-binding proteins during the late stages of Flavivirus replication cycle. <i>Virology Journal</i> , 2020, 17, 60.	3.4	22
48	Long-Term Protection Elicited by a DNA Vaccine Candidate Expressing the prM-E Antigen of Dengue Virus Serotype 3 in Mice. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 87.	3.9	9
49	Two Is Better Than One: Evidence for T-Cell Cross-Protection Between Dengue and Zika and Implications on Vaccine Design. <i>Frontiers in Immunology</i> , 2020, 11, 517.	4.8	31
50	Dengue and COVID-19, overlapping epidemics? An analysis from Colombia. <i>Journal of Medical Virology</i> , 2021, 93, 522-527.	5.0	73
51	Characterization of the Type-Specific and Cross-Reactive B-Cell Responses Elicited by a Live-Attenuated Tetavalent Dengue Vaccine. <i>Journal of Infectious Diseases</i> , 2021, 223, 247-257.	4.0	12
52	Immunogenicity of a Live-Attenuated Dengue Vaccine Using a Heterologous Prime-Boost Strategy in a Phase 1 Randomized Clinical Trial. <i>Journal of Infectious Diseases</i> , 2021, 223, 1707-1716.	4.0	15
53	Randomized trials of housing interventions to prevent malaria and Aedes-transmitted diseases: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2021, 16, e0244284.	2.5	18
54	Considerations for patients with psoriasis travelling under immunosuppression. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 197-207.	0.8	2
55	Three-year Efficacy and Safety of Takeda's Dengue Vaccine Candidate (TAK-003). <i>Clinical Infectious Diseases</i> , 2022, 75, 107-117.	5.8	101

#	ARTICLE	IF	CITATIONS
56	A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans. <i>Nature Communications</i> , 2021, 12, 1102.	12.8	40
58	Arbovirus Rash in the Febrile Returning Traveler as a Diagnostic Clue. <i>Current Tropical Medicine Reports</i> , 2021, 8, 91-98.	3.7	4
59	Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003). <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009258.	3.0	27
60	Emergence and Autochthonous Transmission of Dengue Virus Type I in a Low-Epidemic Region in Southeast China. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 638785.	3.9	2
61	Is Dengue Vaccine Protection Possible?. <i>Clinical Infectious Diseases</i> , 2022, 74, 156-160.	5.8	8
62	Geographical heterogeneity and socio-ecological risk profiles of dengue in Jakarta, Indonesia. <i>Geospatial Health</i> , 2021, 16, .	0.8	6
63	Reducing dengue fever cases at the lowest budget: a constrained optimization approach applied to Thailand. <i>BMC Public Health</i> , 2021, 21, 807.	2.9	4
64	Phage display demonstrates durable differences in serological profile by route of inoculation in primary infections of non-human primates with Dengue Virus 1. <i>Scientific Reports</i> , 2021, 11, 10823.	3.3	2
65	A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses. <i>Journal of Virology</i> , 2021, 95, .	3.4	37
66	Persistence of neutralizing antibody and its protective efficacy induced by a live attenuated tetravalent dengue vaccine, KD-382, in cynomolgus monkeys. <i>Vaccine</i> , 2021, 39, 3169-3178.	3.8	1
67	Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2021, 45, 1.	1.1	8
68	Vaccines and Senior Travellers. <i>Frontiers in Aging</i> , 2021, 2, .	2.6	4
69	Knowledge gaps in the epidemiology of severe dengue impede vaccine evaluation. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e42-e51.	9.1	20
70	Dengue vaccine: an update. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1495-1502.	4.4	22
71	Cost-effectiveness of dengue vaccination in Puerto Rico. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009606.	3.0	8
72	Emerging Mosquito-Borne Viruses Linked to <i>Aedes aegypti</i> and <i>Aedes albopictus</i> : Global Status and Preventive Strategies. <i>Vector-Borne and Zoonotic Diseases</i> , 2021, 21, 731-746.	1.5	24
73	Identification of potential biomarkers in dengue via integrated bioinformatic analysis. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009633.	3.0	5
74	Comparison of Neutralizing Dengue Virus B Cell Epitopes and Protective T Cell Epitopes With Those in Three Main Dengue Virus Vaccines. <i>Frontiers in Immunology</i> , 2021, 12, 715136.	4.8	9

#	ARTICLE	IF	CITATIONS
75	Optimal Control of Dengue Transmission with Vaccination. <i>Mathematics</i> , 2021, 9, 1833.	2.2	6
76	Dengue virus: epidemiology, biology, and disease aetiology. <i>Canadian Journal of Microbiology</i> , 2021, 67, 687-702.	1.7	99
77	Tenovin-1 inhibited dengue virus replication through SIRT2. <i>European Journal of Pharmacology</i> , 2021, 907, 174264.	3.5	10
78	Vaccine-Associated Enhanced Viral Disease: Implications for Viral Vaccine Development. <i>BioDrugs</i> , 2021, 35, 505-515.	4.6	16
79	Modeling Dengue Immune Responses Mediated by Antibodies: A Qualitative Study. <i>Biology</i> , 2021, 10, 941.	2.8	9
80	Challenges in prevaccination screening for previous dengue infection. <i>The Lancet Global Health</i> , 2021, 9, e4-e5.	6.3	3
82	Identification and selection of immunodominant B and T cell epitopes for dengue multi-epitope-based vaccine. <i>Medical Microbiology and Immunology</i> , 2021, 210, 1-11.	4.8	10
83	Dengue Vaccines: The Promise and Pitfalls of Antibody-Mediated Protection. <i>Cell Host and Microbe</i> , 2021, 29, 13-22.	11.0	24
84	Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination. <i>Journal of Infectious Diseases</i> , 2022, 225, 1521-1532.	4.0	45
86	The economic impact and cost-effectiveness of combined vector-control and dengue vaccination strategies in Thailand: results from a dynamic transmission model. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008805.	3.0	6
87	Broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics. <i>ELife</i> , 2019, 8, .	6.0	44
88	Serum IL-18 Is a Potential Biomarker for Predicting Severe Dengue Disease Progression. <i>Journal of Immunology Research</i> , 2021, 2021, 1-15.	2.2	2
89	Targets and strategies for vaccine development against dengue viruses. <i>Biomedicine and Pharmacotherapy</i> , 2021, 144, 112304.	5.6	15
92	Stimulation of B Cell Immunity in Flavivirus-Naïve Individuals by the Tetravalent Live Attenuated Dengue Vaccine TV003. <i>Cell Reports Medicine</i> , 2020, 1, 100155.	6.5	6
93	Dengue Vaccines: An Update. <i>Pediatric Infectious Disease</i> , 2020, 2, 32-33.	0.0	0
94	Stimulation of B Cell Immunity in Flavivirus-Naïve Individuals by the Tetravalent Live Attenuated Dengue Vaccine TV003. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
95	Development and Characterization of a Multiplex Assay to Quantify Complement-Fixing Antibodies against Dengue Virus. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12004.	4.1	4
96	Wolbachia detection in <i>Aedes aegypti</i> using MALDI-TOF MS coupled to artificial intelligence. <i>Scientific Reports</i> , 2021, 11, 21355.	3.3	5

#	ARTICLE	IF	CITATIONS
100	Efficacy of Tetravalent Dengue Vaccine: A Systematic Review and Meta-Analysis. <i>Indian Journal of Community Medicine</i> , 2021, 46, 191-194.	0.4	0
101	Hematologic Parameters of Acute Dengue Fever Versus Other Febrile Illnesses in Ambulatory Returned Travelers. <i>Current Infectious Disease Reports</i> , 2021, 23, 1.	3.0	5
103	Discovery of B-cell epitopes for development of dengue vaccines and antibody therapeutics. <i>Medical Microbiology and Immunology</i> , 2022, 211, 1-18.	4.8	3
104	Characterization of the cell-mediated immune response to Takeda's live-attenuated tetravalent dengue vaccine in adolescents participating in a phase 2 randomized controlled trial conducted in a dengue-endemic setting. <i>Vaccine</i> , 2022, 40, 1143-1151.	3.8	9
105	Dengue virus RNA detection rates in blood donors correlates with local infection incidences during a dengue outbreak in Taiwan. <i>Journal of Infectious Diseases</i> , 2022, , .	4.0	1
107	The effects of vaccination, vector controls and media on dengue transmission dynamics with a seasonally varying mosquito population. <i>Results in Physics</i> , 2022, 34, 105298.	4.1	8
108	Effect of General Cross-Immunity Protection and Antibody-Dependent Enhancement in Dengue Dynamics. <i>Computational and Mathematical Methods</i> , 2022, 2022, 1-22.	0.8	1
109	Transcriptome-wide changes in gene expression, splicing, and lncRNAs in response to a live attenuated dengue virus vaccine. <i>Cell Reports</i> , 2022, 38, 110341.	6.4	7
110	Host immunity and vaccine development against Dengue virus. , 2022, , .		3
111	Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines. <i>Frontiers in Immunology</i> , 2022, 13, 840104.	4.8	22
112	Mathematical models for dengue fever epidemiology: A 10-year systematic review. <i>Physics of Life Reviews</i> , 2022, 40, 65-92.	2.8	46
113	Modeling Dengue Immune Responses Mediated by Antibodies: Insights on the Biological Parameters to Describe Dengue Infections. <i>Computational and Mathematical Methods</i> , 2022, 2022, 1-11.	0.8	7
114	Traditional Knowledge to Contemporary Medication in the Treatment of Infectious Disease Dengue: A Review. <i>Frontiers in Pharmacology</i> , 2022, 13, 750494.	3.5	6
115	Overview of paratransgenesis as a strategy to control pathogen transmission by insect vectors. <i>Parasites and Vectors</i> , 2022, 15, 112.	2.5	26
116	Use of analgesics/antipyretics in the management of symptoms associated with COVID-19 vaccination. <i>Npj Vaccines</i> , 2022, 7, 31.	6.0	21
117	A novel chimeric dengue vaccine candidate composed of consensus envelope protein domain III fused to C-terminal-modified NS1 protein. <i>Vaccine</i> , 2022, 40, 2299-2310.	3.8	2
118	Prevention and control of dengue and chikungunya in Colombia: A cost-effectiveness analysis. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0010086.	3.0	3
119	Single dose of chimeric dengue-2/Zika vaccine candidate protects mice and non-human primates against Zika virus. <i>Nature Communications</i> , 2021, 12, 7320.	12.8	1

#	ARTICLE	IF	CITATIONS
120	Tetravalent formulation of polymeric nanoparticle-based vaccine induces a potent immune response against dengue virus. <i>Biomaterials Science</i> , 2022, 10, 2917-2928.	5.4	1
121	Incidence of dengue fever in Israeli travelers 2008–2019. <i>Travel Medicine and Infectious Disease</i> , 2022, , 102330.	3.0	1
122	Designing vaccine candidates against dengue virus by in silico studies on structural and nonstructural domains. <i>Molecular and Cellular Probes</i> , 2022, 63, 101818.	2.1	4
124	Dengue: A Growing Problem With New Interventions. <i>Pediatrics</i> , 2022, 149, .	2.1	28
125	The knowledge, attitude and practice of community people on dengue fever in Central Nepal: a cross-sectional study. <i>BMC Infectious Diseases</i> , 2022, 22, 454.	2.9	8
126	Dengue Vaccines: An Update. <i>BioDrugs</i> , 2022, 36, 325-336.	4.6	34
127	Clinical Safety Experience of TAK-003 for Dengue Fever: A New Tetravalent Live Attenuated Vaccine Candidate. <i>Clinical Infectious Diseases</i> , 2023, 76, e1350-e1359.	5.8	11
128	Immunoinformatics Aided Design and In-Vivo Validation of a Cross-Reactive Peptide Based Multi-Epitope Vaccine Targeting Multiple Serotypes of Dengue Virus. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	19
129	Estimating the Time Reproduction Number in Kupang City Indonesia, 2016–2020, and Assessing the Effects of Vaccination and Different Wolbachia Strains on Dengue Transmission Dynamics. <i>Mathematics</i> , 2022, 10, 2075.	2.2	8
130	Dengue Seroprevalence and Factors Associated with Dengue Seropositivity in Petaling District, Malaysia. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 7170.	2.6	5
131	Specificity and Breadth of the Neutralizing Antibody Response to a Live-Attenuated Tetravalent Dengue Vaccine. <i>Journal of Infectious Diseases</i> , 2022, 226, 1959-1963.	4.0	8
132	Controlled Human Infection Models To Accelerate Vaccine Development. <i>Clinical Microbiology Reviews</i> , 2022, 35, .	13.6	12
133	A multiple-target mRNA-LNP vaccine induces protective immunity against experimental multi-serotype DENV in mice. <i>Virologica Sinica</i> , 2022, 37, 746-757.	3.0	3
134	Mice immunized with trimethyl chitosan nanoparticles containing DENV-2 envelope domain III elicit neutralizing antibodies with undetectable antibody-dependent enhancement activity. <i>Journal of General Virology</i> , 2022, 103, .	2.9	2
135	Time-dependent force of infection and effective reproduction ratio in an age-structure dengue transmission model in Bandung City, Indonesia. <i>Infectious Disease Modelling</i> , 2022, 7, 430-447.	1.9	0
136	Current Vaccine Platforms in Enhancing T-Cell Response. <i>Vaccines</i> , 2022, 10, 1367.	4.4	8
137	Dengue vaccine development: challenges and prospects. <i>Current Opinion in Infectious Diseases</i> , 2022, 35, 390-396.	3.1	10
138	Vaccine History: From Smallpox to Covid-19. <i>Engineering Materials</i> , 2022, , 519-543.	0.6	0

#	ARTICLE	IF	CITATIONS
139	Efficacy of Dengue Vaccines in the Prevention of Severe Dengue in Children: A Systematic Review. <i>Cureus</i> , 2022, , .	0.5	0
140	Evolution of inflammation and immunity in a dengue virus 1 human infection model. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	13
142	Dengue vaccine poised for roll-out but safety concerns linger. <i>Nature</i> , 2022, 611, 434-435.	27.8	12
143	Preparedness for the Dengue Epidemic: Vaccine as a Viable Approach. <i>Vaccines</i> , 2022, 10, 1940.	4.4	8
144	Can the triumph of mRNA vaccines against COVID-19 be extended to other viral infections of humans and domesticated animals?. <i>Microbes and Infection</i> , 2023, 25, 105078.	1.9	0
145	A fast-growing dengue virus mutant reveals a dual role of STING in response to infection. <i>Open Biology</i> , 2022, 12, .	3.6	4
146	Biologics for dengue prevention: up-to-date. <i>Expert Opinion on Biological Therapy</i> , 0, , 1-15.	3.1	3
147	Antibodies Produced in Response to a Live-Attenuated Dengue Vaccine are Functional in Activating the Complement System. <i>Journal of Infectious Diseases</i> , 0, , .	4.0	1
149	Neutralization fingerprinting technology for characterizing polyclonal antibody responses to dengue vaccines. <i>Cell Reports</i> , 2022, 41, 111807.	6.4	0
150	A cluster-randomized, placebo-controlled trial to evaluate the efficacy of a spatial repellent (Mosquito Shield [®] , [®]) against Aedes-borne virus infection among children 4-16 years of age in the Gampaha District, Sri Lanka: study protocol (the AEGIS program). <i>Trials</i> , 2023, 24, .	1.6	1
151	Diseases spectrum in the field of spatiotemporal patterns mining of infectious diseases epidemics: A bibliometric and content analysis. <i>Frontiers in Public Health</i> , 0, 10, .	2.7	2
152	Management of Dengue: An Updated Review. <i>Indian Journal of Pediatrics</i> , 2023, 90, 168-177.	0.8	12
153	A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country. <i>Vaccine</i> , 2023, 41, 1398-1407.	3.8	7
154	Challenges on the development of a dengue vaccine: a comprehensive review of the state of the art. <i>Journal of General Virology</i> , 2023, 104, .	2.9	11
155	Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue. <i>American Journal of Tropical Medicine and Hygiene</i> , 2023, 108, 722-726.	1.4	3
156	Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study. <i>PLoS Neglected Tropical Diseases</i> , 2023, 17, e0011124.	3.0	5
157	An experimental medicine decipher of a minimum correlate of cellular immunity: Study protocol for a double-blind randomized controlled trial. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
158	A live dengue virus vaccine carrying a chimeric envelope glycoprotein elicits dual DENV2-DENV4 serotype-specific immunity. <i>Nature Communications</i> , 2023, 14, .	12.8	9

#	ARTICLE	IF	CITATIONS
159	Grand challenges in major tropical diseases: Part II. <i>Frontiers in Tropical Diseases</i> , 0, 4, .	1.4	2
163	Dengue: Update on Clinically Relevant Therapeutic Strategies and Vaccines. <i>Current Treatment Options in Infectious Diseases</i> , 2023, 15, 27-52.	1.9	20
164	A dengue vaccine whirlwind update. <i>Therapeutic Advances in Infectious Disease</i> , 2023, 10, 204993612311672.	1.8	3
165	Is new dengue vaccine efficacy data a relief or cause for concern?. <i>Npj Vaccines</i> , 2023, 8, .	6.0	27
166	Dengue as a Disease Threatening Global Health: A Narrative Review Focusing on Latin America and Brazil. <i>Tropical Medicine and Infectious Disease</i> , 2023, 8, 241.	2.3	7
167	Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults. <i>Npj Vaccines</i> , 2023, 8, .	6.0	1
168	The effects of public health measures on severe dengue cases: An optimal control approach. <i>Chaos, Solitons and Fractals</i> , 2023, 172, 113577.	5.1	2
169	Qdenga® - A promising dengue fever vaccine; can it be recommended to non-immune travelers?. <i>Travel Medicine and Infectious Disease</i> , 2023, 54, 102598.	3.0	9
170	Development of virus-like particles with inbuilt immunostimulatory properties as vaccine candidates. <i>Frontiers in Microbiology</i> , 0, 14, .	3.5	1
171	Clinical Characteristics and Outcomes Among Travelers With Severe Dengue. <i>Annals of Internal Medicine</i> , 2023, 176, 940-948.	3.9	8
172	Advances in mRNA vaccines for viral diseases. <i>Journal of Medical Virology</i> , 2023, 95, .	5.0	2
173	Insights into dengue immunity from vaccine trials. <i>Science Translational Medicine</i> , 2023, 15, .	12.4	2
174	A stochastic B cell affinity maturation model to characterize mechanisms of protection for tetravalent dengue vaccine constructs. <i>Frontiers in Molecular Biosciences</i> , 0, 10, .	3.5	0
175	Technologies for Making New Vaccines. , 2023, , 1350-1373.e9.		0
176	Imported and autochthonous dengue in Spain. <i>Revista Científica Española de Medicina Tropical</i> , 2023, , .	0.5	1
177	Dengue Vaccines. , 2023, , 275-285.e6.		0
178	A Phase 1, double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a tetravalent live attenuated dengue vaccine in adults. <i>Vaccine</i> , 2023, 41, 5614-5621.	3.8	0
181	Severe dengue in the intensive care unit. <i>Journal of Intensive Medicine</i> , 2023, , .	2.1	0

#	ARTICLE	IF	CITATIONS
182	Measuring dengue illness intensity: Development and content validity of the dengue virus daily diary (DENV-DD). <i>Journal of Patient-Reported Outcomes</i> , 2023, 7, .	1.9	0
183	Mitigating the effects of climate change on human health with vaccines and vaccinations. <i>Frontiers in Public Health</i> , 0, 11, .	2.7	1
184	Flaviviruses: Dengue. , 2023, , 1-65.		0
187	Nanomedicine as a potential novel therapeutic approach against the dengue virus. <i>Nanomedicine</i> , 0, , .	3.3	0
188	Safety and durable immunogenicity of the TV005 tetravalent dengue vaccine, across serotypes and age groups, in dengue-endemic Bangladesh: a randomised, controlled trial. <i>Lancet Infectious Diseases</i> , The, 2024, 24, 150-160.	9.1	6
189	Seroprevalence of Dengue and Chikungunya Virus Infections in Children Living in Sub-Saharan Africa: Systematic Review and Meta-Analysis. <i>Children</i> , 2023, 10, 1662.	1.5	1
190	An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	3.3	0
191	Vaccines and sera. , 2024, , 15-62.		0
192	Consistency of immunogenicity in three consecutive lots of a tetravalent dengue vaccine candidate (TAK-003): A randomized placebo-controlled trial in US adults. <i>Vaccine</i> , 2023, , .	3.8	0
193	Dengue Vaccination: Towards a New Dawn of Curbing Dengue Infection. <i>Immunological Investigations</i> , 2023, 52, 1096-1149.	2.0	0
194	Symmetry in a multi-strain epidemiological model with distributed delay as a general cross-protection period and disease enhancement factor. <i>Communications in Nonlinear Science and Numerical Simulation</i> , 2024, 128, 107663.	3.3	1
195	Dengue Virus: Molecular Biology and Recent Developments in Control Strategies, Prevention, Management, and Therapeutics. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2023, 14, 107-124.	0.4	0
196	Homotypic antibodies target novel E glycoprotein domains after natural DENV 3 infection/vaccination. <i>Cell Host and Microbe</i> , 2023, 31, 1850-1865.e5.	11.0	1
197	A call for blinding assessments in dengue vaccine trials. <i>Lancet Infectious Diseases</i> , The, 2024, 24, e10.	9.1	0
198	Dengue virus infection and neurological manifestations: an update. <i>Brain</i> , 2024, 147, 830-838.	7.6	0
199	Ocular Manifestations of Flavivirus Infections. <i>Pathogens</i> , 2023, 12, 1457.	2.8	0
200	Integrated control strategies for dengue, Zika, and Chikungunya virus infections. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
202	Annals of Education: Teaching Climate Change and Global Public Health. <i>International Journal of Environmental Research and Public Health</i> , 2024, 21, 41.	2.6	0

#	ARTICLE	IF	CITATIONS
203	Marked enhancement of the immunogenicity of plant-expressed <sc>IgG</sc> fusion proteins by inclusion of cholera toxin non-toxic B subunit within the single polypeptide. <i>Plant Biotechnology Journal</i> , 2024, 22, 1402-1416.	8.3	0
204	The epidemiology of imported and locally acquired dengue in Australia, 2012–2022. <i>Journal of Travel Medicine</i> , 2024, 31, .	3.0	0
205	Development of Vaccines against Emerging Mosquito-Vectored Arbovirus Infections. <i>Vaccines</i> , 2024, 12, 87.	4.4	0
206	Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4–5-year results from a phase 3, randomised, double-blind, placebo-controlled trial. <i>The Lancet Global Health</i> , 2024, 12, e257-e270.	6.3	3
207	Three Dengue Vaccines – What Now?. <i>New England Journal of Medicine</i> , 2024, 390, 464-465.	27.0	0
208	Live, Attenuated, Tetravalent Butantan Dengue Vaccine in Children and Adults. <i>New England Journal of Medicine</i> , 2024, 390, 397-408.	27.0	4
209	Dengue Fever Epidemics and the Prospect of Vaccines: A Systematic Review and Meta-Analysis Using Clinical Trials in Children. <i>Diseases (Basel, Switzerland)</i> , 2024, 12, 32.	2.5	0
210	Evolving Spectrum of Dengue: A Two-Year Experience From a Tertiary Care Hospital in Pakistan. <i>Cureus</i> , 2024, , .	0.5	0
211	Seroprevalence of dengue IgG and associated risk factors in symptomatic and asymptomatic adults in Posadas (Misiones, Argentina), 2017-2019. <i>Journal of Infection and Public Health</i> , 2024, 17, 663-668.	4.1	0
212	Immunological signatures unveiled by integrative systems vaccinology characterization of dengue vaccination trials and natural infection. <i>Frontiers in Immunology</i> , 0, 15, .	4.8	0
213	Quadrivalent dengue-virus vaccines: challenges and opportunities for India. <i>Lancet Infectious Diseases</i> , The, 2024, 24, e270-e271.	9.1	0